cas 6011-14-9|| where to buy Aminoacetonitrile Hydrochloride

Produktname:Aminoacetonitrile Hydrochloride

IUPAC Name:2-aminoacetonitrile hydrochloride

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM117483-1000g	in stock	ǫȯ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6011-14-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:6011-14-9; Molekulare Formel:C2H5ClN2; Schmelzpunkt:-; SMILES-Code:N#CCN.[H]Cl; Dichte:

: Katalognummer:CM117483; Molekulargewicht:92.53; Siedepunkt:; Mdl-Nr.:MFCD00012850; Lagerung:

: Nitrogen Compounds; Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.

: Momelotinib; GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.